DNA Next Generation Sequencing Market is expected to reach US$ 22,716.9 Million by 2025

PRESS RELEASE BY The Insight Partners 21 Jan 2019

Share this press on

DNA Next Generation Sequencing Market: Key Insights

According to our new research study on “DNA Next Generation Sequencing Market Forecast to 2025 –Global Analysis – by Product, Application, End User, and Geography,” the global DNA next generation sequencing market size is estimated to reach US$ 22,716.9 million by 2025 from US$ 4,898.5 million in 2017; it is estimated to grow at a CAGR of 21.7% during 2018–2025. The report highlights trends prevailing in the market and factors driving its growth. The DNA next generation sequencing market growth is attributed to the increasing prevalence of cancer across the globe, rising research studies, increasing collaborations between research institutes and DNA Next Generation Sequencing market players along with increasing applications of DNA next generation sequencing. However, the high cost associated with the process may hinder the growth of market.

North America held the largest share DNA next generation sequencing, with the US holding the largest market share, followed by Canada. Canada is expected to witness the highest growth over the forecast period. The growth in North America DNA next generation sequencing market is characterized by increasing focus of market players in the US and Canada, grants & funds by NIH in the US, and rising prevalence of cancer cases across North America. Moreover, the US market is expected to witness growth opportunities owing to factors such as strong presence of biopharmaceutical and biotechnological companies.

DNA Next Generation Sequencing Market

DNA Next Generation Sequencing Market

DNA Next Generation Sequencing Market Report to 2025

Download Free Sample

DNA Next Generation Sequencing Market to 2025 - Global Analysis and Forecasts By Product (Platforms, Services and Consumables); Application (Diagnostics, Drug Discovery, Precision Medicine, & Other Applications); & End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals Clinics, & Other End Users) and Geography

In recent years, DNA next generation sequencing market players began focusing on strengthening their presence in the US. These companies undergo various organic and inorganic growth strategies to enhance its presence in the US. For instance, in March 2018, Thermo Fisher acquired IntegenX, which provides rapid DNA technology. The aim of this acquisition was to enhance Thermo’s product portfolio. Additionally, in August 2017, Illumina and Telegraph together launched Verogen, a new company. This company will provide Illumina’s forensic sequencing technology to forensic customers. These strategies taken up by the market players is likely to strengthen the growth in the regional market.

Furthermore, National Institutes of Health (NIH), a part of the US Department of Health and Human Services, provides funds and grants in the field of genomics and sequencing. For instance, in September 2015, NIH provided six new grants that supported researchers. Also, in July 2013, NIH awarded four grants for up to four years to research teams to explore the use of genome sequencing in medical care.

Thus, the above-mentioned factors are expected to offer growth opportunities in North America and worldwide. On the other hand, Asia Pacific is expected to witness the highest growth over the forecast period. In 2019, the Next Generation Sequencing Facility promised to sequence up to 30 human genomes in a day and help researchers individually tag genomes of up to 80,000 cells in 8 minutes.

The increasing prevalence of cancer is expected to fuel the DNA next generation sequencing market growth

In recent years, cancer cases have increased tremendously, and the trend is anticipated to remain the same in the upcoming years. Change in lifestyle has resulted in more exposure to oncogenic factors. According to Canadian Cancer Society, the researchers estimated that there would be 229,200 new cancer cases and 84,600 cancer deaths in Canada in 2021. Cancer can be cured if diagnosed and treated at an initial stage. Cancer sequencing using next-generation sequencing (NGS) methods provides ample opportunities in the field of oncology. Additionally, NGS aids in the diagnostics and treatment of cancer. Increase in cancer cases is expected to be a prime factor to drive the market in the coming years.

DNA Next Generation Sequencing Market: Segmental Overview

Product-Based Insights

The global market, based on product, is segmented into platforms, services, and consumables. The platform segment is further sub-segmented into HiSeq Series, MiSeq Series, SOLiD, Ion Torrent, Pacbio Rs II and Sequel Systems, and others. Further, the services segment is sub-segmented into sequencing services and data management and analysis services. The consumables segment is also sub-segmented into sample preparation consumables and other NGS consumables. The consumables segment held a larger share among the product subsegments in 2017 and is also anticipated to follow a similar trend over the forecast period. Consumables depend on various requirements to be performed in the preparation of the genome library. The robotic systems require larger amounts, in turn, increases the cost of the sample. The consumables are used in the numerous stages of the next-generation sequencing procedures, including sample generation, storing the samples and their purification, preparation of the library and quantification, and PCR amplification.

Application-Based Insights

The global market, based on application, is segmented into diagnostics, drug discovery, precision medicine, and other applications. The diagnostics segment held the largest share in 2017 and is expected to witness significant growth over the next five to six years. Clinical laboratories have increasingly adopted next-generation sequencing (NGS) as a standard for diagnosing hereditary disorders. Depending upon the specific focus of the diagnostic laboratory, NGS methods can be used to detect either germline or somatic mutations.

End User-Based Insights

The global market, based on end user, is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and other end users. NGS can also be used to predict the response to or adverse effects of drugs or to calculate appropriate drug dosage. This led hospitals and clinics to use this technology significantly, which would generate better outcomes and be more patient-centric.

The academic & research institutes are receiving funds from various organizations for research and development to improve NGS. In December 2017, according to the data of National Science Foundation (NSF), total university-performed R&D reached US$ 55 billion per year. Of these US$ 55 billion, universities have shares of approximately US$ 12 billion. Furthermore, in March 2018, German Research Foundation (DFG) funded four new German sequencing centers with around €14 million (US$ 17.3 million). The four centers will be equipped with next-generation sequencing technology and will offer consulting services for sequencing projects and bioinformatics.

DNA Next Generation Sequencing Market: Competitive Landscape and Key Developments

Thermo Fisher Scientific INC; Illumina, Inc; Qiagen N.V.; Beijing Genomics Institute; PerkinElmer, Inc.; F.Hoffman-La Roche Ltd.; Agilent Technologies; Eurofins Scientific; Oxford Nanopore Technologies Ltd.; and Macrogen Inc. are among the leading companies in the market. The market share is anticipated to flourish with the development of new innovative products by market players.

  • In December 2018, Illumina, Inc launched new high-density genotyping array, the Infinium Global Diversity Array. This new array was developed for and inspired by the All of Us Research Program. This will allow the program to accelerate the unprecedented effort to complete genotyping and sequencing for all 1 million or more people who participate in the program.
  • In November 2018, QIAGEN launched new bioinformatics analysis tool. The new tool incorporates the best of two previous QIAGEN products CLC Biomedical Genomics Workbench and CLC Genomics Workbench.
  • In July 2018, Oxford Nanopore released an updated version of the software that drives the company’s MinION, GridION and PromethION sequencing devices. This helps improve performance, make the technology easier to use, and includes plenty of new features.
  • In December 2017, Roche received approval from the US Food and Drug Administration (FDA) for FoundationOne CDx, a comprehensive companion diagnostic assay for oncology care. Roche acquired a majority stake in Foundation Medicine in April 2015 and has been actively commercializing the latter’s services portfolio outside the US and other countries.

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

Download Free PDF Brochure